Recent Advancements of Treatment for Leptomeningeal Carcinomatosis
Treatment of Leptomeningeal carcinomatosis (LMC) from solid cancers has not advanced noticeably since the introduction of intra-cerebrospinal fluid (CSF) chemotherapy in the 1970's. The marginal survival benefit and difficulty of intrathecal chemotherapy injection has hindered its wide spread u...
Main Authors: | Gwak, Ho-Shin, Lee, Sang Hyun, Park, Weon Seo, Shin, Sang Hoon, Yoo, Heon, Lee, Seung Hoon |
---|---|
Format: | Online |
Language: | English |
Published: |
The Korean Neurosurgical Society
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534733/ |
Similar Items
-
Retrospective Analysis of Cerebrospinal Fluid Profiles in 228 Patients with Leptomeningeal Carcinomatosis : Differences According to the Sampling Site, Symptoms, and Systemic Factors
by: Shim, Youngbo, et al.
Published: (2016) -
Incidence and Risk Factors for Leptomeningeal Carcinomatosis in Breast Cancer Patients with Parenchymal Brain Metastases
by: Jung, Jong-myung, et al.
Published: (2012) -
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
by: Park, Won-Young, et al.
Published: (2016) -
Leptomeningeal Carcinomatosis of Gastric Cancer Misdiagnosed as Vestibular Schwannoma
by: Kim, Shin-Jae, et al.
Published: (2014) -
Chest Wall Pain as the Presenting Symptom of Leptomeningeal Carcinomatosis
by: Sim, Kyoung Bo, et al.
Published: (2014)